Results: BCR-ABL fusion gene detection by D-FISH showed ABL-BCR deletion on derivative 9 in 47.8% of nonresponders which was higher as compared to pretreatment (11%
INTRODUCTION
Approximately 5%-10% of chronic myeloid leukemia (CML) patients carry a variant Philadelphia (Ph) chromosome translocation in which the Ph chromosome is derived through rearrangements other than the classic t(9;22). Ph chromosome is formed when the 3' end of the c-ABL protooncogene (ABL) at 9q34 is relocated to the 5' end of the Breakpoint Cluster Region (BCR) gene at 22q11.2 producing the BCR-ABL hybrid gene on the derivative 22 and 3' end of BCR is translocated to 9q34 downstream from the 5'ABL site, resulting in the reciprocal ABL-BCR fusion gene on the derivative 9 (1). It has been generally thought that patients with classic and variant Ph translocations have the same molecular changes and are clinically and hematologically identical (1) . Variant Ph translocations involving several partner chromosomes seem to be more frequently associated with additional chromosomal abnormalities unrelated to the Ph formation (2) . It has been reported that ABL deletion on derivative 9 was associated with poor prognosis while BCR deletion did not affect survival in CML (3, 4) . However, role of ABL-BCR fusion gene is not well documented (5) . A dual color dual fusion Fluorescence In-situ Hybridization (D-FISH) BCR-ABL probe system has been designed to span the translocation breakpoints labeled with different fluorochromes to detect deletion in ABL or BCR or ABL-BCR on derivative 9. D-FISH BCR/ABL probe is used to monitor residual disease in CML using interphase nuclei as well as it reveals the locations of 3'ABL and 5'BCR as well as 5'ABL and 3'BCR on metaphase chromosomes (6) . It has been presented at American Society for Clinical Oncology annual meeting in 2007 that deletion in derivative 9 in Chinese patients with CML showed poor prognosis using D-FISH system (7) . However, such reports are needed from Asian countries like India to validate the geographic correlation of CML patients with derivative 9 deletions and prognosis of the patients. Therefore the present study aimed to analyze CML patients with deletion in 3'BCR and/ or 5'ABL and/or ABL-BCR on derivative 9 to predict disease prognosis in CML patients at the time of diagnosis and during follow-up.
METHODS

Subjects and samples
The study included blood and bone marrow samples from 78 pretreatment (PT) CML patients at the time of diagnosis and their 90 follow-up samples from the medical oncology department of The Gujarat Cancer and Research Institute. Follow-up samples were classified as complete responders (CR, n=33), non responders (NR, n =54) and partial responders (PR, n=3) based on the treatment response. Imatinib was given to all the patients as per the protocol. Clinical details of the patients are given in 
Study ethics
The study design and patients consent to participate in the study was ethically approved by hospital based ethical committee of the Institute. 
Methods
Conventional cytogenetic analysis
Statistical analysis
Data were statistically analyzed using SPSS statistical software (version 13.0; SPSS, Inc., Chicago, IL, USA). Student t test was performed to compare follow-up duration between patients responded and not responded to therapy. Pearson correlation test was used to assess association between conventional cytogenetic and D-FISH results. Statistical significance was considered when 'p' values were less than 0.05. Table 2 shows frequency of karyotype in pretreatment and follow-up samples. PT samples showed 43.6% non informative for t(9;22), 53.8% were positive for t(9;22), 1.3% normal karyotype while 1.3% complex karyotype in addition to t(9;22). CR showed 6% non informative and 93.93% normal karyotype. NR showed 20.37% non informative, 74.08% for t(9;22), 1.85% normal, 1.85% complex and 1.85% with mixed clone. PR showed 33.3% each of non informative, t(9;22) and mixed clone by cytogenetics. 
RESULTS
Conventional cytogenetics:
Conventional cytogenetics and D-FISH in patients who responded to therapy
Conventional cytogenetics and D-FISH in patients who did not respond to therapy
Representative D-FISH pattern of a nonresponder patient
A 37 year old female diagnosed as CML-CP with 6% bone marrow blasts in (Figure 2 A-D) .
DISCUSSION
The present study aimed to detect whether deletion of ABL or BCR or ABL-BCR on derivative 9 can predict disease prognosis in CML patients at the time of diagnosis and during follow-up and to discusses the present results with other reported controversial observations and suggest the prospect for further research in this direction. In the present study, complex variant translocation by karyotype was seen in 1 to 2% of PT and NR. It has been widely accepted that the clinical, prognostic, and hematological features of CML patients with complex variant translocations are not different from those with the classical t(9;22) translocation because pathological event is the formation of the BCR/ABL fusion gene (12) . D-FISH is useful in two ways; first, when conventional cytogenetic is non informative and second when conventional cytogenetics is informative but it cannot detect submicroscopic deletions on derivative 9. However, D-FISH alone cannot be performed because conventional cytogenetics is important to identify partner chromosome in three way translocation. Therefore ours and others findings suggest that interpretation of results should be made in light with conventional cytogenetic and FISH (10) . Similarly, deletion of ABL-BCR (OGY) on derivative 9 was seen in 11.1% of PT which was comparable with reported 15%-20% cases in CML (13) (14) (15) . While deletion in ABL, BCR or complex three way translocation (OGGY, OOGY, OOGGY) was seen in 22.2% of PT which is comparable with 24.4% of patients reported by Lee et al (16) . Deletion of any of the BCR or ABL genes on derivative chromosome 9 was reported to be associated with shorter overall and event free survival resulting into poor prognosis (15, 16) . Patients with ABL-BCR deletion represented by OGY variant signal pattern by D-FISH were not different in terms of clinical or laboratory features. This observation has been confirmed by others who also reported shorter chronic phase duration (17) , a poor response to alpha interferon therapy (17) , and a higher incidence of post bone marrow transplant relapse rate (13 Table 4 ) as compared to those patient who did not respond to therapy (62%, Table 5 ). Therefore deletion in ABL, BCR, or ABL-BCR on derivative 9 was not associated with response to therapy as seen in a representative case of responder diagnosed with CML-CP showing t(9;22) and 76% cells with ABL-BCR deletion by D-FISH (Figure 1 A and B) . After 12 months patient's karyotype was 46,XX and D-FISH result was 99.6% of the cells negative for the fusion gene (OOGG, Figure 1 C and D). Our patients who responded to the therapy showed controversial results (16) showing significantly longer follow-up duration as compared to patients who did not respond to therapy (95% C.I. 2.99-8.77 months, p=0.001). In this study we found that even 1% of cells with BCR-ABL fusion gene was detected using D-FISH probe. This is in accordance with the earlier report of 1% minimal residual disease detection limit of D-FISH probe (17) . It has been reported that deletion in derivative 9 is associated with shorter chronic phase (13, 14, 18) . A representative case as mentioned in figure-2 was diagnosed as CML-CP, D-FISH was performed on 22 nd day of the initial diagnosis. The BM morphology showed blast crisis with 80% blasts with D-FISH showed ABL-BCR deletion (OGY) in derivative 9 in 77.4% cells. However, it is not known why the time interval from chronic phase to blast crisis varies among CML patients (19) . We have observed that average interval from chronic phase to blast crisis is 3.5 months, accelerated to blast crisis is 16.5 months and chronic to accelerated phase is 18 months from the date of diagnosis. In this study deletion on derivative 9 was heterogeneous involving either ABL or BCR, or ABL-BCR. This raises the question which region of the derivative 9 is important for disease prognosis. Many tumor-related genes are located near the translocation breakpoints (14) . It has been reported that p21rac acts on cell growth and proliferation associated with RAS, which moves along with 3'BCR region on derivative 9 during translocation. GTPase-activating protein binds with p21rac and inhibits its activity. Therefore, a loss of this region can induce abnormal cell growth and proliferation (20) . If these genes are deleted during BCR-ABL gene rearrangement and the residue allele is injured by "two hit" events, the tumor suppressor functions are destroyed and the disease can progress. Similarly argininosuccinate synthetase (ASS) gene located on 9q34 region adjacent to ABL and Immunoglobulin light chain (IGLL1) gene located near BCR gene on chromosome 22 might be candidate genes to analyze along with deletion in ABL-BCR on derivative 9 (21) . Therefore, an array of adjacent genes at the breakpoint and fusion regions needs to be analyzed using Bacterial Artificial Chromosome (BAC) FISH clones. We are currently working on the BACs for different chromosome 9 and 22 breakpoint and fusion regions in cases with deletion in derivative 9.
In conclusion, variant D-FISH signal pattern involving deletion in ABL, BCR or ABL-BCR on derivative 9 did not correlate with response to therapy. Though this is the first small study from India, the results should be validated on large scale. Tumor related genes adjacent to breakpoint and fusion region of BCR and ABL need to be analyzed using bacterial artificial chromosome (BAC) FISH for the deletion status and must be correlated along with the derivative 9 deletion and clinical response to the therapy. Our group has been developing home-brew FISH probes using BAC clones for breakpoint and fusion region of chromosome 9 and 22 for wider research application.
